IndyGeneUS AI operates at the forefront of the biofintech and longevity sectors by integrating genomics, artificial intelligence (AI), and blockchain technologies. The company focuses on transforming how individuals manage and benefit from their genomic data, aiming to enhance health outcomes while also creating economic opportunities. By leveraging advanced data mining techniques and AI, IndyGeneUS Bio accelerates the development and manufacturing of targeted therapies, particularly addressing health disparities faced by African diaspora populations. Their mission emphasizes the importance of precision medicine, aiming to bring high-quality, equitable healthcare solutions to underserved communities.

As a contract development and manufacturing organization (CDMO), IndyGeneUS Bio offers a comprehensive suite of services that streamline the process of bringing advanced therapies to market. Their capabilities include viral vector manufacturing, cell therapy bioprocessing, and extensive analytical testing, all conducted under current Good Manufacturing Practices (cGMP). The company is dedicated to optimizing processes for both autologous and allogeneic cellular therapies, ensuring scalability from pre-clinical stages to commercial production. By providing a patient-centric approach and a client-driven model, IndyGeneUS Bio aims to deliver high-quality therapeutic solutions efficiently, thereby positioning itself as a leader in the development of gene and cell therapies.

United States

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity.

IndyGeneUS AI

Company Details